Start Date
April 30, 2023
Primary Completion Date
August 31, 2024
Study Completion Date
December 31, 2024
EP0057
EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
Olaparib tablets
Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
Tapei Medical University - Shuang-Ho Hospital Ministry of Health and Welfare, New Taipei City
Changhua Christian Hospital, Changhua
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Chest Hospital, Shanghai
Linyi Cancer Hospital, Linyi
The First Affiliated Hospital of Xiamen University, Fujian
Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South, Changsha
Henan Cancer Hospital, Henan
Shanxi Cancer Hospital, Shanxi
Affiliated Hospital of Hebei University, Baoding
Seoul St. Mary Hospital, Seoul
Dong-A University Hospital, Busan
Seoul National University Bundang Hospital, Seoul
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Chungbuk National University Hospital, Cheongju-si
Cha University Bundang Medical Center, Gyeonggi-do
Chang Gung Medical Foundation Linkou, Taoyuan District
Chi Mei Hospital Liouying, Tainan City
South Korea University Hospital, Seoul
Lead Sponsor
Ellipses Pharma
INDUSTRY